Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

Why is Porsche leaving Germany's DAX index? How will Amazon ending Prime shipping sharing affect members? What caused the recent drop in Figma's stock? Why did ConocoPhillips announce major layoffs? How is Trump's tariff case impacting US trade policy? What led to the $425 million fine against Google? How will the upcoming jobs report influence Fed decisions?

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

investors.com/news/technology/arrowhead-pharmaceuticals-novartis-parkinsons-disease

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug, sending Arrowhead stock surging.
The post Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-09-02 13:50:08.